Alcidion Group Limited (AU:ALC)
ASX:ALC
Want to see AU:ALC full AI Analyst Report?
ALC Stock Chart & Stats
AU$0.10
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.10
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.15
Previous CloseN/A
Volume609.88K
Average Volume (3M)796.98K
Market Cap
AU$147.72M
Enterprise ValueAU$134.85M
Total Cash (Recent Filing)AU$14.20M
Total Debt (Recent Filing)AU$1.32M
Price to Earnings (P/E)26.5
Beta0.92
Next Earnings
Sep 02, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,342,952,600
10 Day Avg. Volume536,053
30 Day Avg. Volume796,979
Financial Highlights & Ratios
PEG Ratio-0.70
Price to Book (P/B)1.57
Price to Sales (P/S)3.38
P/FCF Ratio24.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.14Price Target Upside40.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$51.05M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue growth of 14.45% indicates progressing market adoption of Alcidion's clinical software and expanding contract scope. For a software-driven hospital IT vendor this durable top-line expansion supports scale benefits, recurring subscription lift, and potential upsell across existing customers over the next several quarters.
Very High Gross MarginAn 88.24% gross margin is typical of software-focused solutions and signals low incremental cost to serve additional users. That structural margin advantage supports sustainable profitability as revenues scale, allowing capacity for continued product investment, implementation support, and margin preservation versus peers reliant on hardware or services-heavy models.
Strong Cash Generation And Low LeverageA massive improvement in free cash flow (3,584.97% growth) and FCF-to-net income ~0.98, combined with a debt-to-equity of 0.016, indicates the company now converts earnings to cash reliably while carrying minimal financial risk. This durable cash and balance-sheet strength underpins reinvestment, M&A optionality, and resilience through healthcare budget cycles.
Bears Say
Negative EBIT MarginA negative EBIT margin points to persistent operating expense pressure relative to core earnings, suggesting the business still requires structural adjustments to reach operating profitability. Over a 2–6 month horizon this undermines sustainable margin improvement unless cost base, pricing, or scale efficiencies are realized.
Thin Net Profit MarginA 4.06% net margin shows limited conversion of high gross profit into retained earnings. Even with strong revenue and gross margins, low net profitability constrains the firm's ability to self-fund growth and increases sensitivity to cost inflation or pricing pressure, posing a structural headwind to durable profitability enhancement.
Modest Return On EquityROE of 1.88% signals the company is generating limited returns on shareholders' capital. Over the medium term this raises questions about capital allocation effectiveness and whether current growth and margin trends will translate into meaningful shareholder value, especially if operating margins remain depressed.
Alcidion Group Limited News
ALC FAQ
What was Alcidion Group Limited’s price range in the past 12 months?
Alcidion Group Limited lowest share price was AU$0.08 and its highest was AU$0.14 in the past 12 months.
What is Alcidion Group Limited’s market cap?
Alcidion Group Limited’s market cap is AU$147.72M.
When is Alcidion Group Limited’s upcoming earnings report date?
Alcidion Group Limited’s upcoming earnings report date is Sep 02, 2026 which is in 129 days.
How were Alcidion Group Limited’s earnings last quarter?
Alcidion Group Limited released its earnings results on Feb 25, 2026. The company reported AU$0.001 earnings per share for the quarter, beating the consensus estimate of AU$0 by AU$0.001.
Is Alcidion Group Limited overvalued?
According to Wall Street analysts Alcidion Group Limited’s price is currently Undervalued.
Does Alcidion Group Limited pay dividends?
Alcidion Group Limited does not currently pay dividends.
What is Alcidion Group Limited’s EPS estimate?
Alcidion Group Limited’s EPS estimate is <0.01.
How many shares outstanding does Alcidion Group Limited have?
Alcidion Group Limited has 1,342,952,600 shares outstanding.
What happened to Alcidion Group Limited’s price movement after its last earnings report?
Alcidion Group Limited reported an EPS of AU$0.001 in its last earnings report, beating expectations of AU$0. Following the earnings report the stock price went down -4.545%.
Which hedge fund is a major shareholder of Alcidion Group Limited?
Currently, no hedge funds are holding shares in AU:ALC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alcidion Group Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$0.14 (40.00% Upside)
AU$0.14 (40.00% Upside)
Blogger Sentiment
Bullish
AU:ALC Sentiment 100%
Sector Average 72%
Sector Average 72%
Technicals
SMA
Positive
20 days / 200 days
Momentum
66.66%
12-Months-Change
Fundamentals
Return on Equity
4.37%
Trailing 12-Months
Asset Growth
3.82%
Trailing 12-Months
Company Description
Alcidion Group Limited
Alcidion Group Limited, together with its subsidiaries, engages in the development and licensing of healthcare software products in Australia, New Zealand, and the United Kingdom. The company offers Miya Precision, a consolidated fast healthcare interoperability resource (FHIR) based platform to deliver smart healthcare; Smartpage, a smartphone and web-based system for hospital communication and task management to address the requirements of clinical and non-clinical users; Patientrack, a real-time patient monitoring and risk screening solution; Silverlink, a patient administration system; and ExtraMed, a clinical and patient flow management software. It also provides product implementation, product support and maintenance, systems integration, and data analysis services. The company was formerly known as Alcidion Corporation Pty Ltd and changed its name to Alcidion Group Limited in December 2015. Alcidion Group Limited was founded in 2000 and is headquartered in South Yarra, Australia.
ALC Stock 12 Month Forecast
Average Price Target
AU$0.14
▲(40.00% Upside)
Technical Analysis
Oneview Healthcare Chess Depository Interests repr 1
―
Mach7 Technologies
―
Beamtree Holdings Ltd
―
Singular Health Group Ltd
―
PainChek Ltd
―
Options Prices
Currently, No data available
---